

Status: Currently Official on 16-Feb-2025  
Official Date: Official Prior to 2013  
Document Type: USP Monographs  
DocId: GUID-13C5F6D5-3D36-4939-AEBE-A163F644BB3C\_1\_en-US  
DOI: [https://doi.org/10.31003/USPNF\\_M52600\\_01\\_01](https://doi.org/10.31003/USPNF_M52600_01_01)  
DOI Ref: e1jag

© 2025 USPC  
Do not distribute

## Methylergonovine Maleate Tablets

» Methylergonovine Maleate Tablets contain not less than 90.0 percent and not more than 110.0 percent of the labeled amount of methylergonovine maleate ( $C_{20}H_{25}N_3O_2 \cdot C_4H_4O_4$ ).

**Packaging and storage**—Preserve in tight, light-resistant containers.

**USP REFERENCE STANDARDS (11)**—

[USP Methylergonovine Maleate RS](#)

**Identification**—

**A:** The  $R_f$  values of the principal fluorescent spot and the principal blue spot in the chromatogram of the *Test preparation* correspond to those in the chromatogram of the *Standard preparation*, as obtained in the test for *Related alkaloids* under *Ergonovine Maleate*, using the Tablets instead of Ergonovine Maleate.

**B:** Transfer a quantity of powdered Tablets, equivalent to about 4 mg of methylergonovine maleate, to a separator, add 20 mL of water, and render alkaline to litmus with sodium carbonate solution (1 in 10). Extract with three 20-mL portions of chloroform, filter the combined chloroform extracts into a small evaporating dish, and evaporate on a steam bath to dryness. Dissolve the residue in a mixture of 6 mL of water and 0.3 mL of hydrochloric acid, and filter, if necessary: the solution so obtained exhibits a bluish fluorescence under UV light. To this solution, add 2 mL of a solution of glacial acetic acid in ethyl acetate (1 in 2), and stratify 2 mL of sulfuric acid, by pipetting, under the solution: a bluish purple ring appears at the interface of the two liquids.

**DISSOLUTION (711)**—

*Medium:* tartaric acid solution (1 in 200); 900 mL.

*Apparatus 2:* 75 rpm.

*Time:* 30 minutes.

*Procedure*—Filter a portion of the solution under test into a flask. Concomitantly determine the fluorescence intensity of this solution in comparison with a Standard solution of [USP Methylergonovine Maleate RS](#) in the same medium having a known concentration of about 0.22 µg per mL in a fluorometer at an excitation wavelength of about 327 nm and an emission wavelength of about 428 nm, using tartaric acid solution (1 in 200) as the blank.

*Tolerances*—Not less than 70% (Q) of the labeled amount of  $C_{20}H_{25}N_3O_2 \cdot C_4H_4O_4$  is dissolved in 30 minutes.

**UNIFORMITY OF DOSAGE UNITS (905):** meet the requirements.

**Related alkaloids**—[NOTE—Conduct this test without exposure to daylight and with the minimum exposure to artificial light.]

*Solvent mixture*—Mix 75 volumes of chloroform, 25 volumes of methanol, and 1 volume of ammonium hydroxide.

*Detecting reagent*—Cautiously dissolve 800 mg of *p*-dimethylaminobenzaldehyde in a mixture of alcohol and sulfuric acid (10:1:1).

*Test preparation*—Transfer a quantity of finely powdered Tablets, equivalent to 5.0 mg of methylergonovine maleate, to a suitable container, add 50 mL of *Solvent mixture*, and stir with the aid of a magnetic stirrer for 40 minutes. Filter, rinsing the container with two 10-mL portions of *Solvent mixture*. Evaporate the combined filtrates in vacuum at 25° to 30°, and dissolve the residue in 2.0 mL of *Solvent mixture*.

*Standard stock solution*—Transfer 25 mg of [USP Methylergonovine Maleate RS](#) to a 10-mL volumetric flask, add *Solvent mixture* to volume, and mix to obtain a solution having a known concentration of 2.5 mg per mL.

*Standard preparations A, B, C, and D*—Dilute accurately measured volumes of *Standard stock solution* quantitatively with *Solvent mixture* (designated below as parts by volume of *Standard stock solution* in total parts by volume of the finished *Standard preparation*) to obtain *Standard preparations*, designated below by letter, having the following concentrations and percentage assignments:

A: (1 in 20); 125 µg per mL (5.0%).

B: (1 in 33); 75 µg per mL (3.0%).

C: (1 in 100); 25 µg per mL (1.0%).

D: (1 in 200); 12.5 µg per mL (0.5%).

*Procedure*—Apply separately 20 µL of the *Test preparation* and 20 µL of each *Standard preparation* to a suitable thin-layer chromatographic plate (see [Chromatography \(621\)](#)) coated with a 0.25-mm layer of chromatographic silica gel mixture. Dry the plate with the aid of a stream of cool air. Position the plate in a chromatographic chamber, and develop the chromatograms in *Solvent mixture* until the solvent front has

moved about three-fourths of the length of the plate. Remove the plate from the developing chamber, mark the solvent front, and allow the solvent to evaporate in a stream of cool air. Examine the plate under long-wavelength UV light. Mark the principal and any secondary fluorescent spots. Spray the plate with *Detecting reagent*, and mark the principal and secondary blue spots. Compare the intensities of any secondary spots observed in the chromatogram of the *Test preparation* with those of the principal spots in the chromatograms of the *Standard preparations*: the sum of the intensities of secondary spots obtained from the *Test preparation* corresponds to not more than 5.0% of related compounds.

**Assay**—[NOTE—Conduct this procedure with a minimum exposure to light.]  
*Mobile phase, Solvent mixture, Standard preparation, and Chromatographic system*—Proceed as directed in the Assay under *Methylergonovine Maleate*.

*Assay preparation*—Place 10 Tablets in 1500-mL volumetric flask, add 400 mL of *Solvent mixture*, and shake by mechanical means for 15 minutes or until completely disintegrated. Dilute with *Solvent mixture* to volume, and mix. Allow the solution to settle for not less than 30 minutes before use, and then filter to obtain the *Assay preparation*.

*Procedure*—Separately inject equal volumes (about 10 µL) of the *Standard preparation* and the *Assay preparation* into the chromatograph, record the chromatograms, and measure the responses for the major peaks. Calculate the quantity, in mg, of methylergonovine maleate (C<sub>20</sub>H<sub>25</sub>N<sub>3</sub>O<sub>2</sub> · C<sub>4</sub>H<sub>4</sub>O<sub>4</sub>) in the portion of Tablets taken by the formula:

$$(L/D)(C)(r_U/r_S)$$

in which *L* is the labeled quantity, in mg, of methylergonovine maleate in each Tablet, *D* is the concentration, in µg per mL, of methylergonovine maleate in the *Assay preparation*, based on the labeled quantity per Tablet and the extent of dilution, *C* is the concentration, in µg per mL, of [USP Methylergonovine Maleate RS](#) in the *Standard preparation*, and *r<sub>U</sub>* and *r<sub>S</sub>* are the responses obtained from the *Assay preparation* and the *Standard preparation*, respectively.

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
METHYLERGONOVINE MALEATE TABLETS	<a href="#">Documentary Standards Support</a>	SM52020 Small Molecules 5
REFERENCE STANDARD SUPPORT	RS Technical Services <a href="mailto:RSTECH@usp.org">RSTECH@usp.org</a>	SM52020 Small Molecules 5

**Chromatographic Database Information:** [Chromatographic Database](#)

**Most Recently Appeared In:**  
Pharmacopeial Forum: Volume No. PF 26(6)

**Current DocID:** GUID-13C5F6D5-3D36-4939-AEBE-A163F644BB3C\_1\_en-US  
**DOI:** [https://doi.org/10.31003/USPNF\\_M52600\\_01\\_01](https://doi.org/10.31003/USPNF_M52600_01_01)  
**DOI ref:** [e1jag](#)